Efficacy and Durability of Repetitive Transcranial Magnetic Stimulation on Cognitive Function in Patients With Mild-to-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.

PsychogeriatricsSep 1, 2026
Clinical ResearchNeurologyPsychiatry

Qian Zhou, Meng-Xia Yang, Qian-Qian Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of repetitive transcranial magnetic stimulation (rTMS) on cognitive function in 143 patients with mild to moderate Alzheimer's disease. The analysis found a small-to-moderate improvement in MMSE scores (g = 0.41, p = 0.021), indicating that rTMS may enhance cognitive function, particularly with excitatory protocols targeting the left dorsolateral prefrontal cortex.

Key findings

  • rTMS resulted in a small-to-moderate improvement in MMSE scores (g = 0.41, p = 0.021).
  • Excluding studies with methodological concerns yielded a similar effect size (g = 0.46).
  • Treatment duration was identified as a significant moderator (β = -0.193, p = 0.034).
  • Follow-up analyses suggested a trend towards sustained benefits (g = 0.25).

Why it matters

The findings suggest that rTMS may offer a non-invasive option to improve cognitive function in patients with mild to moderate Alzheimer's disease, which could be beneficial in managing symptoms and enhancing quality of life.

Source

PubMed · PMID 42705844

Published in Psychogeriatrics. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.